Gene Profiling and Individualized Treatment of Neonatal Seizure in China

What this Trial Is About

Researchers are studying genetic diagnosis and treatment strategies for neonates experiencing seizures within the first year of life, focusing particularly on those with seizure onset before one month of age. The study aims to identify genetic variants using next-generation sequencing (NGS) to better understand the causes and clinical features of neonatal and infant epilepsy. This work supports the development of personalized medicine approaches by comparing genetic and clinical data between groups based on age of seizure onset. The study involves performing genetic sequencing on neonates and infants with severe seizures or intractable epilepsy starting before one year old. The genetic tests focus on genes known to be associated with seizure disorders. The research assesses existing treatments' effects while collecting genetic data to inform future individualized therapies. There is no intervention or drug being tested; instead, this is an observational study gathering detailed genetic and clinical information. Participants will be monitored from seizure onset through up to six months afterward to evaluate seizure frequency and genetic mutation rates. The study collects data on mutation rates of common seizure genes, with genetic sequencing possibly taking up to three months to complete. Researchers will assess seizure control and treatment responses over six months to improve understanding of neonatal seizure disorders. Participation duration varies based on individual seizure onset and follow-up timing.

Etiology and Treatment of Neonatal Seizure